Literature DB >> 30027427

The Burden of Untreated HCV Infection in Hospitalized Inmates: a Hospital Utilization and Cost Analysis.

Alysse G Wurcel1,2, Deirdre J Burke3, Jianing J Wang4, Brian Engle5, Kathryn Noonan6, Tamsin A Knox5, Arthur Y Kim7, Benjamin P Linas4.   

Abstract

Hepatitis C virus (HCV) is highly prevalent in incarcerated populations. The high cost of HCV therapy places a major burden on correctional system healthcare budgets, but the burden of untreated HCV is not known. We investigated the economic impact of HCV through comparison of length of stay (LOS), frequency of 30-day readmission, and costs of hospitalizations in inmates with and without HCV using a 2004-2014 administrative claims database. Inmates with HCV had longer LOS, higher frequency of 30-day readmission, and increased cost of hospitalizations. Costs were higher in inmates with HCV even without advanced liver disease and in inmates with HIV/HCV compared to HCV alone. We conclude that although HCV treatment may not avert all of the observed increases in hospitalization, modest reductions in hospital utilization with HCV cure could help offset treatment costs. Policy discussions on HCV treatment in corrections should be informed by the costs of untreated HCV infection.

Entities:  

Keywords:  Cost; HIV; Hepatitis C; Hospitalization; Inmate; Readmission

Mesh:

Year:  2018        PMID: 30027427      PMCID: PMC6095754          DOI: 10.1007/s11524-018-0277-z

Source DB:  PubMed          Journal:  J Urban Health        ISSN: 1099-3460            Impact factor:   5.801


  29 in total

1.  Diagnosis related groups and the price of cost containment.

Authors:  K G Sophy
Journal:  J Contemp Health Law Policy       Date:  1986

2.  Hospitalizations and costs associated with hepatitis C and advanced liver disease continue to increase.

Authors:  Fujie Xu; Xin Tong; Andrew J Leidner
Journal:  Health Aff (Millwood)       Date:  2014-10       Impact factor: 6.301

Review 3.  Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden.

Authors:  Zobair Younossi; Haesuk Park; Linda Henry; Ayoade Adeyemi; Maria Stepanova
Journal:  Gastroenterology       Date:  2016-02-26       Impact factor: 22.682

Review 4.  Hepatitis C: an update on the silent epidemic.

Authors:  S A Sarbah; Z M Younossi
Journal:  J Clin Gastroenterol       Date:  2000-03       Impact factor: 3.062

Review 5.  Treatment of hepatitis C: a systematic review.

Authors:  Anita Kohli; Ashton Shaffer; Amy Sherman; Shyam Kottilil
Journal:  JAMA       Date:  2014-08-13       Impact factor: 56.272

6.  HCV-related mortality among male prison inmates in Texas, 1994-2003.

Authors:  Amy J Harzke; Jacques G Baillargeon; Michael F Kelley; Pamela M Diamond; Karen J Goodman; David P Paar
Journal:  Ann Epidemiol       Date:  2009-05-13       Impact factor: 3.797

Review 7.  Treating hepatitis C in the prison population is cost-saving.

Authors:  Jennifer A Tan; Tom A Joseph; Sammy Saab
Journal:  Hepatology       Date:  2008-11       Impact factor: 17.425

Review 8.  Review of statistical methods for analysing healthcare resources and costs.

Authors:  Borislava Mihaylova; Andrew Briggs; Anthony O'Hagan; Simon G Thompson
Journal:  Health Econ       Date:  2010-08-27       Impact factor: 3.046

9.  The impact of methicillin-resistant S. aureus on length of stay, readmissions and costs: a register based case-control study of patients hospitalized in Norway.

Authors:  A Elizabeth S Andreassen; Caroline M Jacobsen; BirgitteFreiesleben de Blasio; Richard White; Ivar Sønbø Kristiansen; Petter Elstrøm
Journal:  Antimicrob Resist Infect Control       Date:  2017-07-06       Impact factor: 4.887

10.  Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study.

Authors:  Jennifer Ann Kieran; Suzanne Norris; Aisling O'Leary; Cathal Walsh; Raphael Merriman; D Houlihan; P Aiden McCormick; Susan McKiernan; Colm Bergin; Michael Barry
Journal:  BMC Infect Dis       Date:  2015-10-26       Impact factor: 3.090

View more
  2 in total

1.  Predictors of hepatitis C treatment outcomes in a harm reduction-focused primary care program in New York City.

Authors:  Jacob Ziff; Trang Vu; Danielle Dvir; Farah Riazi; Wilma Toribio; Scott Oster; Keith Sigel; Jeffrey Weiss
Journal:  Harm Reduct J       Date:  2021-03-31

2.  Hepatitis C Virus Is Associated With Increased Mortality Among Incarcerated Hospitalized Persons in Massachusetts.

Authors:  Alysse G Wurcel; Rubeen Guardado; Curt G Beckwith
Journal:  Open Forum Infect Dis       Date:  2021-12-18       Impact factor: 3.835

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.